Researchers develop blood tests to study ‘biological age’ of the body’s organs and tissues
There can be no either/or in mental health — we must rigorously examine pharmaceutical and social solutions
Focusing on artificial dyes and seed oils misses the true culprit — excess toxic fat
The US appears to be turning its back on a scientific consensus that has relegated several diseases to history
More than a dozen nations struggle to contain outbreak as health systems flounder with loss of international support
Mebufotenin benzoate also requires a much shorter period of clinical supervision in trial
Research offers clues to choosing chemotherapy treatments with fewer long-term side effects
Slashed US aid agency’s funding is expected to harm the fight against diseases including malaria and HIV/Aids
Oxford research shows adjuvant chemicals included in vaccinations may enhance their antiviral effect
The decline in funding for vaccinations poses a worldwide threat
Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
In this monthly series, running alongside our existing Tech Exchange dialogues, FT journalists talk to the scientists, developers and business leaders exploring ever more applications for artificial intelligence, in every aspect of our lives
Cambridge start-up CMR Surgical has innovative technology but it needs global ambition
$140mn financing will allow Draig Therapeutics to move drug candidates into clinical trials
Ruling that NIH’s refusal to pay grants was illegal could lead to funds being reinstated
Expansion of NHS app comes as part of government’s 10-year plan for health service
Paris conference urges international action against synthetic organisms that could disrupt critical ecosystems
Deal would mark latest move by a life sciences group to jettison lower-growth assets
UK’s flagship biomedical laboratory wants to attract scientists fleeing Trump academic crackdown
Real prevalence of condition has remained largely stable since 2020, according to research review
Pharma group estimates Camizestrant could be worth up to $5bn of sales in its peak year
A London-based start-up employs bioprospectors to scour the world for DNA to feed AI models building a digital tree of life
We must recognise and protect the pipelines that lead from research to real-world benefit
If successful, it would be the first new class of drug against certain bacteria strains for more than 50 years
